8,682
Total Claims
$3.4M
Drug Cost
1,410
Beneficiaries
$2,379
Cost/Patient
Peer Comparison vs. 4,479 Interventional Cardiology providers
+126%
Cost per patient vs peers
$2,379 vs $1,054 avg
+44%
Brand preference vs peers
18.9% vs 13.1% avg
Brand vs Generic
81% generic
Brand: 1,639 claims · $3.1M
Generic: 7,043 claims · $234K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Macitentan | 50 | $681K |
| Sacubitril/Valsartan | 398 | $592K |
| Apixaban | 361 | $441K |
| Riociguat | 22 | $309K |
| Empagliflozin | 194 | $290K |
| Ambrisentan | 13 | $172K |
| Dapagliflozin Propanediol | 80 | $118K |
| Rivaroxaban | 61 | $81K |
| Evolocumab | 57 | $60K |
| Ticagrelor | 56 | $54K |
| Semaglutide | 25 | $25K |
| Tirzepatide | 12 | $20K |
| Sildenafil Citrate | 21 | $19K |
| Metoprolol Succinate | 771 | $16K |
| Rosuvastatin Calcium | 557 | $13K |
Prescribing Profile
Patient Profile
73
Avg Age
57%
Female
2.20
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About